ASCO 2019 - Kantar reviews multiple myeloma showdown

ASCO 2019 and the future of oncology

Day three of ASCO 2019 saw a showdown between two anti-CD38 compounds in multiple myeloma, Janssen's Darzalex and Sanofi's isatuximab. Darzalex showed more positive data in newly-diagnosed patients, while isatuximab was making its phase 3 debut. Darzalex aims to fend off Sanofi's rival and also improve the patient experience with its subcutaneous formulation. Kelly Clapp from Kantar reviews the data from the multiple myeloma showdown and provides some thoughts on what it means for the therapy area. [video width="1280" height="720" mp4=""][/video]   Click here to view exclusive live coverage from ASCO 2019.